阿布图斯生物制药
ABUS
4.22
-0.07
-1.63%
阿布图斯生物制药
US · ABUS
#3365 按市值排名
上市于 2015
4.22
-0.07
-1.63%
实时 - 追踪5344个代码 - 心跳于112秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了2家。
- 机构持股总比例下降了4.1个百分点。
机构持股
- 机构持股比例
- 87.03% -4.09pp
- 机构数量
- 204 +2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund36.01%
Hedge Fund26.44%
Public Company19.97%
Private Company3.23%
Individual/Insider0.88%
Family Office/Trust0.78%
Government Pension Fund0.44%
Insurance Company0.16%
Other12.08%
主要股东 截至 2026-10-01
Roivant Sciences Ltd.
15.10% · 29.88M 股
Two Seas Capital LP
9.65% · 19.10M 股
Morgan Stanley Investment Management Inc.
8.65% · 17.12M 股
Whitefort Capital Management, LP
7.98% · 15.79M 股
BlackRock
6.96% · 13.77M 股
Vanguard Capital Management, LLC
4.12% · 8.15M 股
State Street Global Advisors
3.98% · 7.87M 股
Rubric Capital Management LP
3.81% · 7.53M 股
Geode Capital Management, LLC
2.08% · 4.12M 股
Barclays Bank Plc
2.07% · 4.10M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Roivant Sciences Ltd. | -- | 15.10% |
| Michael McElhaugh | COO & Chief Business Officer | 0.69% |
| Tuan Nguyen | Chief Financial Officer | 0.08% |
| Lindsay Androski | Interim President, CEO & Director | 0.04% |
| David Hastings | Chief Financial Officer | 0.03% |
| Robert Beardsley | Director | 0.02% |
| Roger Sawhney | Director | 0.02% |
| J. Naftzger | Chief Compliance Officer | 0.01% |
| Michael Sofia | Chief Scientific Officer | -- |
| Karen Sims | Chief Medical Officer | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Roivant Sciences Ltd. | -- | Sale to Issuer | -8,967,383 | $5.00 |
| 2026-09-17 | Robert Beardsley | Director | Derivative Exercise and Sale | -99,057 | $3.20–5.07 |
| 2026-09-17 | Robert Beardsley | Director | Derivative Exercise and Retained | +32,276 | $3.20 |
| 2026-09-17 | Roger Sawhney | Director | Derivative Exercise and Sale | -100,508 | $3.34–5.07 |
| 2026-09-17 | Roger Sawhney | Director | Derivative Exercise and Retained | +30,825 | $3.34 |
| 2026-09-17 | Lindsay Androski | Interim President, CEO & Director | Derivative Exercise and Sale | -82,527 | $3.20–5.07 |
| 2026-09-17 | Lindsay Androski | Interim President, CEO & Director | Derivative Exercise and Retained | +44,337 | $3.20 |
| 2026-09-17 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Sale | -206,637 | $3.49–5.07 |
| 2026-09-17 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Retained | +86,463 | $3.49 |
| 2026-06-07 | Robert Beardsley | Director | Other Derivative Acquisition | +78,800 | $4.24 |
| 2026-06-07 | Roger Sawhney | Director | Other Derivative Acquisition | +78,800 | $4.24 |
| 2026-02-01 | Lindsay Androski | Interim President, CEO & Director | Other Acquisition | +28,000 | -- |
| 2026-02-01 | Lindsay Androski | Interim President, CEO & Director | Other Derivative Acquisition | +71,700 | $4.39 |
| 2026-02-01 | Tuan Nguyen | Chief Financial Officer | Other Acquisition | +73,500 | -- |
| 2026-02-01 | Tuan Nguyen | Chief Financial Officer | Other Derivative Acquisition | +188,400 | $4.39 |
| 2025-08-03 | Roger Sawhney | Director | Other Derivative Acquisition | +157,600 | $3.34 |
| 2025-04-20 | Michael McElhaugh | COO & Chief Business Officer | Intent to Sell (Form 144) | -246,886 | $3.26 |
| 2025-04-14 | Michael McElhaugh | COO & Chief Business Officer | Intent to Sell (Form 144) | -53,114 | $3.20 |
| 2025-03-30 | Michael Sofia | Chief Scientific Officer | Intent to Sell (Form 144) | -250,000 | $3.50 |
| 2025-03-30 | Tuan Nguyen | Chief Financial Officer | Other Derivative Acquisition | +750,000 | $3.49 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿布图斯生物制药 讨论区 0 条评论